Powassan Virus Cases Rise in US
Analysis based on 8 articles · First reported Jun 29, 2026 · Last updated Jun 30, 2026
The rising cases of Powassan virus in the United States could lead to increased demand for healthcare services and potentially spur research and development in the pharmaceutical and biotechnology industries for treatments or vaccines. The lack of current treatment or vaccine for the Powassan virus means that public health initiatives and preventative measures will be crucial, potentially impacting consumer spending on insect repellents and protective clothing.
The Powassan virus, a rare but dangerous tick-borne illness, is seeing a significant increase in cases across the United States, particularly in the Northeast and Upper Midwest. Transmitted rapidly by deer ticks, the virus can cause severe neurological symptoms, including brain inflammation, and has a fatality rate of up to 15% among symptomatic individuals, with half of survivors experiencing lasting neurological problems. Experts attribute the rise to warmer weather extending tick seasons and boosting host populations, as well as improved testing. As of June 2026, 15 cases have been reported by the United States — Centers for Disease Control and Prevention, with a record 76 cases in 2025. There is currently no specific treatment or vaccine, emphasizing the importance of prevention through tick bite avoidance.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard